A B S T R A C T Hairy cell leukemia is a well described clinical entity, but the cell of origin for this leukemic cell and its function are still unknown. There are no totally specific markers for this cell, although tartrateresistant acid phosphatase staining has been used extensively as a diagnostic test. This study describes three monoclonal murine antibodies with variable specificity for hairy cells. Antibody 1 was highly specific for hairy cells and was not found to react with normal or leukemic cells in this limited study. It did not react with the cells of all patients. It also did not react with all of the hairy cells of some of the positive cases. Antibodies 2 and 3 reacted with virtually all hairy cells but not with normal peripheral blood cells. However, reactions were obtained with certain leukemic myelomonoblasts and some activated B cells. The most obvious use for these three antibodies is for diagnostic purposes. They should also be helpful reagents to investigate the origin of the leukemic hairy cell. The possibility that antibody 1 detects a tumor-specific antigen is discussed.
INTRODUCTION
Hairy cell leukemia (HCL, leukemic reticuloendotheliosis)l is a clinically well defined entity (1) . However, the origin of the hairy cell itself is still controversial, and no normal equivalent of this leukemic cell has been found. The cell is clearly related to the B cell because it possesses the highly specific property of having membrane immunoglobulin M (IgM) and IgD (2-6); it occasionally, however, shows properties of the T cell (7) . Apparently T and B cell phenotypes may coexist or alternate on hairy cells (8) (9) (10) (11) (12) . The T cell phenotype may appear after mitogen stimulation (12) . These observations suggest the presence of subgroups Received for publication 1I January 1982 and in revised form 5 (1) . Demonstration of tartrate-resistant acid phosphatase (TRAP) has been used extensively as a marker for hairy cells in both clinical (13) and experimental situations (7, 14) . This test, however, has been shown not to be totally specific for hairy cells (15) , especially when results show intermediate positivity. HCL with a negative TRAP test has also been described (15) .
The diagnostic usefulness of a hairy cell marker is apparent. Such a marker might also help uncover the true identity and origin of the hairy cell. We have, therefore, used the hybridoma technique to make monoclonal murine antibodies to hairy cell leukemia cells. Three such antibodies with varying degrees of specificity are described in this paper.
METHODS Patients
Cells from 15 E rosettes. Spontaneous rosette formation between lymphocytes and neuraminidase-treated sheep erythrocytes was performed as described elsewhere (17) .
Reagents
Monoclonal antihairy cell antibodies. The hybridoma technique used is described elsewhere (18) . Briefly, BALB/ c mice were immunized with 20 X 106 hairy cells on three occasions over a 7-mo period. 3 d after the last immunization, the spleens of these mice were harvested, and the splenocytes were fused to the murine lymphoma cell line SP 2/0-Ag 14 (19) 
RESULTS
Three monoclonal antibodies, aHCl, aHC2, and aHC3, reacted with the immunizing cells, the hairy cells from patient Ya, but not with normal PBMNC. These were selected for further study. Antibodies aHC2 and aHC3 gave weak granular staining with some variation of intensity when used for indirect immunofluorescence on hairy cells. Antibody aHCI gave brighter and more speckled staining also with variation of intensity (Fig. 1) . Whereas the former two antibodies appeared to stain all hairy cells in the specimen from patient Ya, the latter antibody was clearly negative with some hairy cells (Fig. 1) .
The reactivity of these antibodies was also tested on hairy cells from patient Ya with a cytofluorograf (Fig.  2 ). The tracings show positive fluorescence with hairy cells but not with normal PBMNC. The fluorescence intensity observed with aHC2 and acHC3 was less than the intensity with aHC1. All three antibodies showed somewhat less fluorescence intensity than that observed with monoclonal anti-kappa light chain antibody. The fluorescence curves of aHC2 and aHC3 follow a Gaussian distribution and suggest that all cells are positive with these antibodies. On the contrary, the curve observed with aHC1 indicates the presence of both a negative and a positive cell population. These findings confirm the above visual description of the staining characteristics of these antibodies.
To define the specificity of these anti-hairy cell antibodies, various normal and pathological cell types were used for immunofluorescent staining. As can be seen in Table I In two cases follow-up samples of blood obtained at a later date were tested (Table II) . In patient Ne clinical deterioration had occurred, manifested by an increasing degree of pancytopenia and an enlarging spleen. This correlated with the presence of more hairy cells in the peripheral blood, both by phase microscopy and by immunofluorescence using the aHC reagents. Staining results and the percentage of hairy cells showed little change in patient St over a 3-mo period during which the patient seemed to be deteriorating.
In Table III BMNC were used in each case, except where indicated by: Iph = leukapheresis, spl = spleen. In patient By both samples were obtained simultaneously.
The leukocyte count was routine clinical data. § Assessed by phase microscopy at X1,000 magnification. Neuraminidase-treated sheep erythrocytes. ¶ Usually the aHC antibodies stained cells that were hairy cells by morphology; however occasionally they stained additional cells that had a less typical hairy appearance, as in patients He, Ma, and So.
Each cell that stained positively also had the morphology of hairy cells.
t All hairy cells seen stained with this reagent and the kappa-bearing cells were not hairy cells by morphology. two monoclonal antimonocyte antibodies described previously (20) in all patients with HCL tested (Table  II) . These antibodies stained -20% of normal PBMNC. The results are consistent with reports of monocytopenia in HCL (25). (5), and (c) differences in the occurrence of two hairy cell specific membrane proteins from patient to patient (26) .
DISCUSSION
Some evidence was obtained indicating that aHCI may identify hairy cells found more frequently during clinically progressive disease such as the leukemic phase of HCL. Both aHC2 and aHC3 reacted with the great majority of hairy cells in all patients, but they also reacted with certain other cell types. This was most apparent for the myeloblasts or myelomonoblasts from patients Table IV ). The studies on the cells of patient Wi were repeated four times and in each experiment only aHC3 gave positive results.
Others have described antibodies reacting with hairy cells. Espinouse et al. (27) describe a rabbit antiserum retaining specificity for hairy cells after absorptions with erythrocytes, T cells, monoblastic leukemic cells, and CLL B cells. Brooks et al. (28, 29) describe a monoclonal murine antibody (FMC-7) made by immunization with a common B cell lymphoblastoid line that reacts with a subset of normal B cells, with B cells from -16% of various chronic lymphocytic leukemia patients, and B cells from most prolymphocytic and hairy cell leukemias tested. Neither of these antibodies appear to be identical to the three monoclonal antibodies described in this paper.
The most specific monoclonal antibody of the three described in this paper, aHC1, could not be shown to definitely react with any cells in the normal tissues examined. Thus by this criterion no normal cell equivalent of the hairy cell could be detected, which was one of the objectives of this investigation. However, it may be that the aHC1 antibodies are directed against a specific tumor antigen common to different hairy cell leukemias and would not react with the analogous hypothetical normal cell. If this is indeed the case, this monoclonal antibody is of added interest because of the rarity of human tumor specific antigens. The potential use of this antibody in the therapy of hairy cell leukemia, possibly covalently linked to cytotoxic compounds, deserves consideration. At the moment the most obvious use of these monoclonal antibodies is for diagnostic purposes.
